Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consent Decree Tempers J&J Consumer Outlook Even As Remediation Ends

Executive Summary

Skin-care and OTC product sales helped propel J&J’s consumer business in the fiscal 2015 first quarter, but currency headwinds dragged on results. CFO Dominic Caruso says the firm is stocking shelves more consistently with previously recalled OTCs, but FDA still needs to sign off on J&J’s remediation work before it returns to full manufacturing capacity, and the agency will monitor the company for a further five years under a 2011 consent decree.

Advertisement

Related Content

Missing CAPA Costs J&J $25 Million In Investigation Sparked By OTC Recalls
J&J Pits 5% Minoxidil Rogaine For Women Against ‘Cosmetic, Quick Fixes’
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS019459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel